India not to stop hydroxychloroquine treatment in mild cases
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Indian health authorities have said that Hydroxychloroquine (HCQ) would not be withdrawn as a treatment methodology for Covid-19 patients, arguing that the decision to use it was scientific, even as the US Food and Drug Administration on 15 June withdrew emergency use of the prophylactic.

• HCQ, currently used to treat lupus and rheumatoid arthritis, has split world opinion on its use in Covid-19 management, even as India said the decision was “taken based on risk-benefit assessment.”

• “We have just changed the clinical management guidelines last week. We are not considering any changes just because the US FDA has withdrawn the emergency use for HCQ,” a senior official in the drug controller’s office said.

• The health ministry, experts from ICMR and DGCI reviewed the clinical management protocol for Covid-19 on June 13 and limited HCQ’s use to management of moderate patients, advising that it be avoided in patients with "severe disease".

• Meanwhile, a debate is raging among public health specialists in India over the use of repurposed HCQ for Covid-19 treatment. The ICMR task force has also been divided over the use of the drug.

Source: https://health.economictimes.indiatimes.com/news/diagnostics/india-not-to-stop-hydroxychloroquine-treatment-in-mild-cases/76416429
Dr. T●●●●z H●●●●●●i and 3 others like this2 shares
Like
Comment
Share
Dr. S●●●●●m S●●●●y P●●●●●l
Dr. S●●●●●m S●●●●y P●●●●●l General Medicine
Interesting read!
Jun 23, 2020Like1